Evidence map›Paper›PMID 37485041›Full record

ArticlePhotoacoustics2023

Dynamic 2-deoxy-D-glucose-enhanced multispectral optoacoustic tomography for assessing metabolism and vascular hemodynamics of breast cancer.

Zheng Han, William M MacCuaig, Metin N Gurcan, Juan Claros-Sorto, Tabitha Garwe, Christina Henson, Jennifer Holter-Chakrabarty, Bethany Hannafon, Vishal Chandra, Elizabeth Wellberg and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Photoacoustics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Zheng HanDepartment of Surgery, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
William M MacCuaigDepartment of Surgery, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
Metin N GurcanCenter for Biomedical Informatics, Wake Forest Baptist Health, Winston-Salem, NC 27101, USA.
Juan Claros-SortoDepartment of Surgery, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
Tabitha GarweDepartment of Biostatistics and Epidemiology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
Christina HensonDepartment of Internal Medicine, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
Jennifer Holter-ChakrabartyDepartment of Internal Medicine, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
Bethany HannafonDepartment of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
Vishal ChandraDepartment of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
Elizabeth WellbergDepartment of Pathology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
Lacey R McNallyDepartment of Surgery, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
University of Oklahoma Health Sciences Center · USAtrium Health Wake Forest Baptist · USUniversity of Oklahoma · US

Funding

Non-Invasive Detection of Tumor Extracellular pH using Multispectral Optoacoustic TomographyR01CA205941 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MCNALLY, LACEY R · 2016 to 2021
$1.7M
Development of an apoptosis biosensor for monitoring of breast cancerR01EB034731 · NIBIB · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HENARY, MAGED M, MCNALLY, LACEY R · 2023 to 2025
$1.5M
Tumor-Specific Nanocontrast Agents for Improved Detection of Pancreatic CancerF31CA261044 · NCI · UNIVERSITY OF OKLAHOMA · PI MACCUAIG, WILLIAM · 2022 to 2023
$79k
NCI NIH HHS F31 CA261044NCI NIH HHS R01 CA205941NIBIB NIH HHS R01 EB034731
6 · The paper itself

Abstract

Clinical tools for measuring tumor vascular hemodynamics, such as dynamic contrast-enhanced MRI, are clinically important to assess tumor properties. Here we explored the use of multispectral optoacoustic tomography (MSOT), which has a high spatial and temporal resolution, to measure the intratumoral pharmacokinetics of a near-infrared-dye-labeled 2-Deoxyglucose, 2-DG-800, in orthotropic 2-LMP breast tumors in mice. As uptake of 2-DG-800 is dependent on both vascular properties, and glucose transporter activity - a widely-used surrogate for metabolism, we evaluate hemodynamics of 2-DG-MP by fitting the dynamic MSOT signal of 2-DG-800 into two-compartment models including the extended Tofts model (ETM) and reference region model (RRM). We showed that dynamic 2-DG-enhanced MSOT (DGE-MSOT) is powerful in acquiring hemodynamic rate constants, including K

Indexed as

2-deoxyglucoseBreast cancerExtended Tofts modelHemodynamicsMetabolismMultispectral optoacoustic tomography, optoacoustic imagingPharmacokineticsPhotoacoustic imagingReference region model

Identifiers

PMID37485041
PMCPMC10362308
OpenAlexW4383671687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.